Combination therapy in the treatment of chronic viral hepatitis and prevention of hepatocellular carcinoma

Treatment of chronic hepatitis B and C viruses (HBV and HCV) is still disappointing, and both are the major causes of liver cirrhosis and hepatocarcinoma. Interferon and lamivudine are the registered drugs for chronic HBV but are scarcely effective on HBeAg-negative patients, and resistance due to v...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	International immunopharmacology 2003-08, Vol.3 (8), p.1169-1176
Hauptverfasser:	Rasi, G, Pierimarchi, P, Sinibaldi Vallebona, P, Colella, F, Garaci, E
Format:	Artikel
Sprache:	eng
Schlagworte:	Adjuvants, Immunologic - therapeutic use Antiviral Agents - therapeutic use Carcinoma, Hepatocellular - prevention & control Chronic viral hepatitis Clinical Trials as Topic Combination therapy with thymosin α1 Drug Therapy, Combination Hepatitis B, Chronic - complications Hepatitis B, Chronic - drug therapy Hepatitis B, Chronic - immunology Hepatitis C, Chronic - complications Hepatitis C, Chronic - drug therapy Hepatitis C, Chronic - immunology Hepatitis, Viral, Human - complications Hepatitis, Viral, Human - drug therapy Hepatitis, Viral, Human - immunology Hepatocellular carcinoma Humans Liver Neoplasms - prevention & control Thymosin - analogs & derivatives Thymosin - therapeutic use
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!